Contrary to our expectation, circulating mRNA analysis using PCA3 showed no significant difference among PCa, BPH, and the control samples, prompting a discussion on the use of urinary circulating mRNAs as PCa biomarkers. This evidence concerns the gene PCA3 and benign prostatic hyperplasia.